A Phase 3 interventional study of Cyclosporine A microemulsion and Placebo in Chronic Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-08-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Psoriasis by Novartis — 3 open to participants now, 4 under way, none of them phase 3. Psoriasis · Novartis.
Among the 68 studies in Psoriasis by Novartis, this one is the 18th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2006, is one of 30 in phase 3, and was the 3rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 68 studies in Psoriasis by Novartis are open now, in 3 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in Spain
Ages 18–100
Novartis Pharmaceuticals · Sites in Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 30 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 177 across the 53 interventional studies, 255 across the 14 observational. Of the 61 that completed or were terminated, 41 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Psoriasis by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382051Novartis PharmaceuticalsModifying PEST for Psoriatic Arthritis Screening | 2026-12-31 |
| NCT07683065Novartis PharmaceuticalsA Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD | 2027-01-15 |
| NCT06142357Novartis PharmaceuticalsSecukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Psoriasis by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy of cyclosporine at 2, 5 mg/kg/day bid (i.e. bis in a day), when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
Drug: Cyclosporine A microemulsion
Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
Drug: Placebo
Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
Also known as: Neoral
Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
Number of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score
PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of severest degree. Relapse is considered a worsening of psoriasis associated to a PASI score \>75% of PASI score recorded before starting induction therapy with CsA (before study start). Each patient was considered as failure (relapse occurrence) if rate was \>= 75%. In all the other cases the patient was considered as success (no relapse).
Time frame: 24 weeks
Proportion of Participants With Clinical Relapse
Clinical relapse was defined as worsening of psoriasis associated with a Psoriasis Area and Severity Index (PASI) \>75% of the PASI score assessed before the continuous treatment, or when the investigator or the patient judged it necessary to change the treatment.
Time frame: 24 weeks
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of the severest degree.
Time frame: baseline and week 24
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
BSA is a measure of the percentage of body surface affected by psoriasis. Using the Mosteller Formula: BSA = BSA (m²) = ( \[Height(in) x Weight(lbs) \]/ 3131 )½ . A covariance analysis was performed on all variables, with value assessed at visit 2 as covariate and center as effect. For each variable the changes versus the last available measures were computed
Time frame: Baseline and week 24
Change From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus
Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 24 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).
Time frame: Baseline and week 24
Safety / Tolerability Assessed by Adverse Events
Time frame: 24weeks
| Milestone | Cyclosporine A | Placebo |
|---|---|---|
| Started | 162 | 81 |
| Intention to treat (itt) population | 160 | 79 |
| Completed | 90 | 38 |
| Not completed | 72 | 43 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Lack of efficacy | 42 | 27 |
| Withdrew: Other | 24 | 15 |
PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of severest degree. Relapse is considered a worsening of psoriasis associated to a PASI score \>75% of PASI score recorded before starting induction therapy with CsA (before study start). Each patient was considered as failure (relapse occurrence) if rate was \>= 75%. In all the other cases the patient was considered as success (no relapse).
| Participants | Cyclosporine A | Placebo |
|---|---|---|
| Success at 6 months | 87 | 36 |
| Failure at 6 months | 73 | 43 |
Clinical relapse was defined as worsening of psoriasis associated with a Psoriasis Area and Severity Index (PASI) \>75% of the PASI score assessed before the continuous treatment, or when the investigator or the patient judged it necessary to change the treatment.
| proportion of participants | Cyclosporine A | Placebo |
|---|---|---|
| Proportion of Participants With Clinical Relapse | 0.369 | 0.456 |
PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of the severest degree.
| Units on a scale | Cyclosporine A | Placebo |
|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Score | 5.70 ± 8.0 | 6.86 ± 8.4 |
BSA is a measure of the percentage of body surface affected by psoriasis. Using the Mosteller Formula: BSA = BSA (m²) = ( \[Height(in) x Weight(lbs) \]/ 3131 )½ . A covariance analysis was performed on all variables, with value assessed at visit 2 as covariate and center as effect. For each variable the changes versus the last available measures were computed
| BSA (m^2) | Cyclosporine A | Placebo |
|---|---|---|
| Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis | 8.12 ± 12.9 | 10.45 ± 16.7 |
Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 24 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis).
| Units on a scale | Cyclosporine A | Placebo |
|---|---|---|
| Change From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus | 17.32 ± 30.9 | 25.44 ± 31.9 |
Results for this outcome have not been posted.
Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporine A | — | 1/160 (0.6%) | 19/160 (11.9%) |
| Placebo | — | 0/79 (0%) | 1/79 (1.3%) |
| Event | Cyclosporine A | Placebo |
|---|---|---|
| Breast massReproductive system and breast disorders | 1/160 | 0/79 |
| Event | Cyclosporine A | Placebo |
|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 12/160 | 1/79 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 8/160 | 0/79 |
| Age, Customized(Participants) | Cyclosporine A | Placebo | Total |
|---|---|---|---|
| between 18-45 years | 100 | 48 | 148 |
| Between 46 and 65 years | 59 | 29 | 88 |
| >=65 years | 1 | 2 | 3 |
| Sex: Female, Male(Participants) | Cyclosporine A | Placebo | Total |
|---|---|---|---|
| Female | 55 | 32 | 87 |
| Male | 105 | 47 | 152 |
The record gives a start of May 2006, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine